XERSMEDIUM SIGNALFINANCIAL10-K

Xeris Pharmaceuticals shows improved liquidity with substantially higher cash reserves, but faces meaningfully increased debt servicing costs alongside continued profitability challenges.

The company's cash position strengthened notably to $111M, providing better runway for operations and R&D investments. However, interest expense grew substantially, indicating increased borrowing costs that could pressure future margins. The maintained cautionary language about achieving profitability suggests ongoing execution risks despite the stronger balance sheet.

Comparing 2026-03-02 vs 2025-03-06View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows a company investing in growth while managing higher financing costs. Cash and equivalents increased substantially to $111M, with current assets and inventory both expanding meaningfully, suggesting stronger working capital management and product stockpiling. However, interest expense grew substantially to $26.6M, while R&D spending increased modestly to $31.2M and SG&A expenses rose to $182.4M, reflecting higher operational and financing costs that could impact the path to profitability.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+73.6%
$15.3M→$26.6M

Interest expense surged 73.6% — significant debt increase or rising rates materially impacting earnings.

Cash & Equivalents
Balance Sheet
+55%
$71.6M→$111.0M

Cash position surged 55% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+43.3%
$167.7M→$240.3M

Current assets grew 43.3% — improving short-term liquidity or inventory/receivables build.

Inventory
Balance Sheet
+42.5%
$48.2M→$68.7M

Inventory surged 42.5% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Accounts Receivable
Balance Sheet
+26.3%
$40.4M→$51.0M

Receivables grew 26.3% — monitor days sales outstanding for collection efficiency.

R&D Expense
P&L
+21.9%
$25.6M→$31.2M

R&D investment increased 21.9% — signals commitment to future product development, though near-term margin impact.

Total Assets
Balance Sheet
+18.7%
$323.1M→$383.5M

Asset base grew 18.7% — expansion through organic growth, acquisitions, or capital deployment.

SG&A Expense
P&L
+11.6%
$163.5M→$182.4M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

LANGUAGE CHANGES
NEW — 2026-03-02
PRIOR — 2025-03-06
ADDED
As of February 27, 2026, 172,431,290 shares, par value $0.0001 per share, of common stock were outstanding.
We have a history of operating losses and may not be able to achieve or sustain profitability in the future, and we may not be able to continue operations without additional fundings.
Management's Discussion and Analysis of Financial Condition and Results of Operations 75 Item 7A.
This Annual Report also contains estimates, projections and other information concerning our industry, our business and the markets for Recorlev, Gvoke and Keveyis and our product candidates.
We offer Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis ("PPP").
We are advancing our Phase 3-ready pipeline product, XP-8121, once-weekly subcutaneous ("SC") levothyroxine, which leverages our proprietary technology XeriSol.
We believe this therapy represents a significant commercial opportunity in the United States, with the potential to generate approximately $1 billion in annual net revenue at peak penetration.
Our Pipeline We prioritize our development efforts on programs that leverage our commercial capabilities or our proprietary formulation technologies, principally our lead pipeline program, XP-8121.
We plan to initiate a Phase 3 clinical trial of XP-8121 in 2026.
The estimated total addressable market for this therapy is 3-5 million patients or more in the United States which we estimate is a $1.0 to $3.0 billion peak net sales opportunity.
REMOVED
As of February 28, 2025, 153,940,135 shares, par value $0.0001 per share, of common stock were outstanding.
We may never be profitable or be able to sustain revenues or, if achieved, sustain profitability in the future and we may not be able to continue operations without additional fundings.
Management's Discussion and Analysis of Financial Condition and Results of Operations 68 Item 7A.
We offer Recorlev for the treatment of Cushing s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis ("PPP").
We leverage our proprietary formulation technologies (XeriSol and XeriJect) in the creation of new products such as our own XP-8121 (once-weekly subcutaneous (SC) levothyroxine) as well as through the formation of development partnerships with other biopharmaceutical companies.
The estimated total addressable market for this therapy is approximately $3.0 billion in the United States.
We are working with the FDA to plan and initiate a Phase 3 clinical trial of our XP-8121 product candidate.
The estimated total addressable market for this therapy is 3-5 million patients or more in the United States which we estimate is a $1.0 billion or greater market opportunity.
We are currently collaborating with several major pharmaceutical companies on the development of formulations of their proprietary therapeutics.
Our Strategy Our strategy is to build a profitable biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →